Launch Therapeutics

Launch Tx provides biotech and biopharma companies with solutions that speed drug candidates’ path to market and connection with investors that provide development funding. Bridging expertise in regulatory strategy, clinical development, clinical operations, manufacturing, and commercialization, we forge a powerfully aligned team focused on the finish. Launch Tx offers a spectrum of custom-tailored collaboration models, from advisory services to complete operational execution. We provide access to innovative technologies and strategic vendor relationships, minimizing risks and optimizing development. Launch Tx is backed by leading investors, Carlyle and its life sciences franchise, Abingworth. Launch Tx was formed in 2022 with the vision of assembling an exceptional team that could redefine late-stage development. The goal? Expediting the pathway for therapies to be approved, and ultimately, delivered to the patients who need them.